Raymond James & Associates’s Axogen AXGN Stock Holding History

Raymond James & Associates’s Portfolio AXGN Stock Details AXGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,573	Closed	-$214K	–	4096
2021 Q1	$214K	Buy	+10,573	New	+$209K	﹤0.01%	3564
2020 Q1	–	Sell	-19,985	Closed	-$358K	–	3507
2019 Q4	$358K	Buy	19,985 +5,535	+38%	+$81.8K	﹤0.01%	2973
2019 Q3	$180K	Buy	14,450 +1,121	+8%	+$18.5K	﹤0.01%	3294
2019 Q2	$264K	Sell	13,329 -2,660	-17%	-$56.9K	﹤0.01%	3083
2019 Q1	$337K	Buy	15,989 +634	+4%	+$11.6K	﹤0.01%	2915
2018 Q4	$314K	Sell	15,355 -890	-5%	-$27.8K	﹤0.01%	2835
2018 Q3	$599K	Buy	+16,245	New	+$709K	﹤0.01%	2588

Other funds holding AXGN

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James & Associates's AXGN Position: Q2 2021 in Review

Raymond James & Associates sold out of Axogen (AXGN) in Q2 2021, closing a stake of 10,573 shares — an estimated $214K sold.

Raymond James & Associates first reported a position in AXGN in Q3 2018 and held it in 7 quarters. The position peaked at $599K in Q3 2018. 128 funds tracked by Wall St. Rank hold AXGN as of Q2 2021.

Raymond James & Associates reported no remaining Axogen position as of Q2 2021 after selling out during the quarter.
Raymond James & Associates sold 10,573 Axogen shares in Q2 2021, an estimated $214K.
Raymond James & Associates first reported a position in Axogen in Q3 2018 and held it in 7 quarters.
Raymond James & Associates's Axogen position peaked at $599K in Q3 2018.
128 funds tracked by Wall St. Rank held Axogen as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.